Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kobayashi Kako Ditches Turnaround Plan with Manufacturing Transfer to Sawai
Embattled generic maker Kobayashi Kako has given up on rebuilding itself from a high-profile GMP scandal that has rattled the industry since late last year, with a decision to transfer its manufacturing facilities and staffers to Big 3 player Sawai…
To read the full story
Related Article
- Kobayashi Kako to Withdraw Marketing License on April 1
March 23, 2023
- Kobayashi Kako to Withdraw Marketing License Next April
June 28, 2022
- 400 Kobayashi Kako Staffers Move to Trust Pharmatech
April 4, 2022
- Kobayashi Kako Manufacturing Unit Now Under Sawai; 170 Staffers Remain for Compensation, Drug Handover
April 1, 2022
- Sawai to Acquire Kobayashi Kako’s Manufacturing Sites, Staffers
December 3, 2021
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
- Viatris Eyes Japan Filing This Year for IgAN Drug
July 1, 2026
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…